Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation
EP Europace
Obesity is a recognised risk factor for reduced atrial fibrillation ablation success and increased recurrence post ablation. In recent years glucagon-like petide-1 receptor agonists (GLP-1RA) have been utilised in clinical practice to treat obesity. The role of GLP-1RA’s in patients with atrial fibrillation is as yet unclear. The authors used a propensity matched population of patients who were initiated on a GLP-1RA in the immediate pre or post ablation period to evaluate the impact of GLP-1RA’s on recurrence of atrial fibrillation post ablation.
